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Abstract 
Background:  Serum  biochemical  liver  tests  (LTs)  (alanine  aminotransferase,  aspartate 
aminotransferase, and gamma glutamyltransferase) and platelet counts are often used to 
screen for chronic liver disease. We determined the prevalence and etiologies of abnormal 
LTs in an adult population in Jilin, China. 
Methods: A total of 3791 individuals between the ages of 18 and 79 years were interviewed 
and then underwent ultrasonography and blood tests.  
Results: The prevalence of abnormal LTs was 14.77% (560 out of 3791 subjects). The risk 
factors for abnormal LTs were non-alcoholic fatty liver disease (NAFLD) alone, which ac-
counted for 11.61%, metabolic syndrome alone for 25%, or both for 22.14%. Abnormal LTs 
were more common in male than in female subjects. The development of abnormal LTs was 
correlated with older age males, increased daily alcohol intake, poor quality of sleep, smoking, 
fasting plasma glucose, body mass index, triglyceridemia, and low-density lipoprotein. Ab-
normal LTs in patients with metabolic syndrome and NAFLD were associated with high 
fasting plasma glucose, triglycerides, body mass index, low density lipoprotein, male, young 
age, poor sleep quality, smoking, and alcohol intake. However, abnormal LTs in patients with 
hepatitis B virus were associated with gender and increased age.  
Conclusions: The results from the current study demonstrated that the prevalence of 
abnormal LTs is high in the population (14.77%). Metabolic syndrome, NAFLD, and alcohol 
intake appear to be potentially important causes of the observed abnormal LTs. 
Key words: alanine aminotransferase; metabolic syndrome; non-alcoholic fatty liver disease; ul-
trasonography; seroepidemiologic marker. 
Introduction 
Chronic liver disease (CLD) is a worldwide pub-
lic  health  concern,  which  often  contributes  to 
end-stage  liver  disease.  The  risk  factors  for  chronic 
liver disease include non-alcoholic fatty liver disease 
(NAFLD),  hepatitis  B  virus  (HBV)  and  hepatitis  C 
virus  (HCV),  and  alcohol  consumption  [1].  Due  to 
increased  unhealthy  dietary  habits  and  sedentary 
lifestyles,  NAFLD,  which  is  associated  with  insulin 
resistance  [2],  has  emerged  as  a  leading  cause  of 
chronic liver disease in Western countries [3-4]. The 
rapidly increasing appearance of metabolic disorders, 
including NAFLD, has also been recently reported in 
China  [5].  Therefore,  the  main  question  is  whether 
there  is  a  similar  change  in  the  etiology  of  chronic Int. J. Med. Sci. 2011, 8 
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liver disease in China. The increasing prevalence of 
obesity, coupled with diabetes, dyslipidemia, hyper-
tension,  and  ultimately  metabolic  syndrome  (MS) 
puts  a  very  large  population  at  risk  of  future  liver 
failure [4, 6]. Before the development of liver failure, 
the course of CLD is usually long and asymptomatic. 
However,  in  early  stages,  alanine  aminotransferase 
(ALT), aspartate aminotransferase (AST), and gamma 
glutamyltransferase  (GGT)  may  increase.  Platelet 
count and indices of hepatic biosynthesis usually de-
crease in advanced stages of CLD. The prevalence and 
etiology of elevated serum aminotransferase levels as 
markers of CLD have been studied in blood donors, 
overweight  adolescents,  and  liver  disease  patients 
[7-9]. But, the results of these studies are likely to have 
selection and referral biases. With regard to the gen-
eral population, relevant data in the period 1988-1994 
have  been  collected  and  published  in  the  United 
States [10-11]. For northern China, where, as in other 
areas  of  Asian  countries,  eating  habits  differ  from 
those in more industrialized areas, relevant data are 
still lacking on NAFLD, MS, and alcohol-induced liv-
er damage. However, it has been shown that NAFLD 
is  the  commonest  cause  of  elevated  ALT  and  pre-
sumed  liver  injury  in  Taiwan  [12].  A  popula-
tion-based  survey  of  serum  biochemical  liver  tests 
could provide a reliable tool to assess potential liver 
diseases, although liver biopsy is the gold standard 
for the diagnosis of fatty liver disease and hepatocel-
lular damage. However, liver biopsy is an invasive, 
inconvenient, and expensive procedure, and carries a 
risk of complications, which is definitely not suitable 
for a population-based study.  Other alternatives in-
clude  ultrasonography  and  computer  tomography, 
which provides an accurate diagnosis for a number of 
liver  diseases,  such  as  fatty  liver.  We  assessed  the 
prevalence and etiology of abnormal liver tests (LTs) 
in the general population of JiLin, China to evaluate 
the potential burden and causes of CLD. 
Materials and Methods 
Design and study population 
A cross-sectional study of aminotransferase lev-
els  and  the  metabolic  factors  (triglyceridemia,  body 
mass  index,  and  low  density  lipoprotein  et  al)  was 
carried out in Dehui, Jilin, China in 2007 (population 
approximately 410,600). Dehui is located 81 km from 
Changchun, the largest city in the area. Earnings of 
most  inhabitants  of  Dehui  are  in  the  middle  of  the 
income range. The sex and age distribution of inhab-
itants are similar to those of JiLin in general. There-
fore, Dehui City is representative of other areas in the 
province in terms of the level of life, economic and 
cultural development.  
A  two-stage,  tiered-system  sampling  method 
was  used.  This  survey  was  comprehensive  and  in-
cluded geographic, economic, cultural, and other pa-
rameters. There are 308 villages and 51 neighborhood 
committees in Dehui. The first survey covered rural 
areas, and the second covered urban areas. Each stage 
was  divided  into  two  layers.  In  the  first  layer,  the 
populations of the villages or neighborhood commit-
tees  were  sorted,  and  the  villages  or  neighborhood 
committees were selected by a computer according to 
the  principle  of  equidistant  random  samples  of  the 
population size. We selected 9 villages and 11 neigh-
borhood committees. In the second layer, the house-
holds were marked by the distance from the centre of 
the  villages  or  neighborhood  committees,  and  they 
were selected according to the principle of equidistant 
random  samples  of  the  distance.  Then,  150-200  or 
80-100 households were computer selected in villages 
or neighborhood committees, respectively. A sample 
of the general population in the selected households 
consisting of individuals who were at least 18 years of 
age and had lived in the same area for more than 10 
years was selected using a systematic random 1 in 3 
sampling procedure from the census list, which had 
been updated on February 1, 2007. 
According to the formula of estimation of sample 
size: N = (t/d) 2 *(1-p) / p (t=1.96, p=0.127 and d=0.1) 
[1],  we  defined  sample  sizes  of  urban  and  rural 
groups. The sizes were 1800 and 2200 based on the 
ratio of urban and rural populations of the area, re-
spectively,  and  the  total  was  4000  (more  than  the 
value N). 
Inclusion  criteria:  at  least 18  years  of  age,  had 
lived in the same area for more than 10 years, was 
selected  from  the  census  list  according  to  the  sam-
pling method. Exclusion criteria: presence of abnor-
mal  autoantibodies,  ceruloplasmin,  and  iron  tests, 
consumption of more than 40 g of alcohol per day.  
In the end, 3920 people responded and agreed to 
participate  in  the  study,  and  their  serum  samples, 
demographic  information,  and  behavioral  factors 
were collected.  
The  response  rate  was  high  (98%,  3920/4000). 
When we analyzed the relationship between  abnor-
mal  liver  tests  and  the  risk  factor,  we  excluded  75 
people  who  had  abnormal  autoantibodies,  cerulo-
plasmin, and iron tests. They consisted of 30, 29, and 
16  people,  respectively.  In  addition,  54  people  who 
reported consuming at least 40 g of alcohol per day 
were  excluded.  In  the  end,  3791  people 
(3920-75-54=3791)(1800 men and 1991 women) were 
eligible for our analyses.  Int. J. Med. Sci. 2011, 8 
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Data and blood collection 
The  study  team  consisted  of  physicians  and 
nurses  who  were  trained  in  the  survey  methods  in 
order to standardize the data collection, interviews, 
blood drawing and handling of serum samples. The 
selected participants were asked to fast overnight (≥8 
h) and attend a local health center for their scheduled 
appointments.  The  selected  subjects  were  visited  at 
home if they could not attend the local health center. 
An interview using the structured questionnaire was 
conducted at the time of the participant’s visit. The 
questionnaire  included  the  following  questions:  (1) 
Do  you sleep  well? (2) Do you smoke? (number  of 
cigarettes per day)? (3) Do you drink alcohol (number 
and type of drinks per day)?  (4) Date of birth, sex, 
place  of  residence.  Information  on  demographics 
(date of birth, sex, place of residence,) and behavioral 
factors  (drinking,  smoking,  sleep  quality)  was  ob-
tained. The study protocol was approved by the In-
stitutional Review Board of the First Hospital of JiLin 
University.  After  written  informed  consent  was  ob-
tained, blood samples were taken from each partici-
pant for seroprevalence analyses. Sera were stored at 
-200C until tested at the First Hospital of JiLin Uni-
versity.  Anthropometric  measurements  including 
height, weight, and waist and hip circumference were 
conducted by well-trained examiners on individuals 
wearing  light  clothing.  Waist  circumference  was 
measured to the nearest 0.1 cm at the midpoint be-
tween the lower borders of the rib cage and the iliac 
crest. Abdominal ultrasonography was performed to 
detect the presence of fatty infiltration in the liver by 
physicians specializing in diagnostic imaging. All of 
whom used standard criteria in evaluating the images 
for hepatic fat [13]. A portable GE Logiq Book ultra-
sound  set  (GE  Yokogawa  Medical  System,  Tokyo, 
Japan)  with  a  3.8-MHz  transducer  was  used.  Fatty 
liver  was  diagnosed  using  ultrasonography  with 
characteristic  findings  of  diffusely  increased  liver 
echogenicity, as evidenced by: liver-kidney contrast, 
blurring  of  the  intrahepatic  vessels  and  the  dia-
phragm  caused  by  diffusely  increased  liver  echo-
genicity, brightness of hepatic echogenicity with loss 
echoes of the posterior hepatic segments and the in-
trahepatic  vessels,  or  invisibility  of  the  diaphragm. 
Fatty liver was diagnosed by concurrence of 3 ultra-
sonographers,  who  were  unaware  of  the  subjects’ 
clinical and biochemical status.  
Serological tests  
HBsAg, HCV antibody, autoantibodies, cerulo-
plasmin,  iron  studies,  glucose,  total  cholesterol, 
LDL-cholesterol, HDL-cholesterol, triglyceride, ALT, 
AST,  and  GGT  were  assayed  by  standard  methods 
with kits from Ke Hua (Shanghai, China). Blood cell 
counts  were  undertaken  using  an  automatic  cell 
counter  (MEK-6318,  Japan).  All  laboratory  analyses 
were performed at the First Hospital of Jilin Univer-
sity. 
Definitions of the abnormal liver tests, metabolic 
syndrome and NAFLD 
Abnormal liver tests, ALT ≥45 IU/L and/or GGT 
≥50  IU/L  and/or  AST  ≥45  IU/L  and/or  platelet 
counts ≤130 X 109/L. These values are consistent with 
the upper or lower limits of normal established by the 
reference  laboratory  for  the  area.  Cases  of  Wilson’s 
disease, autoimmune hepatitis, elevated serum ferri-
tin,  saturated  serum  transferrin,  and  hereditary  he-
mochromatosis  were  excluded.  The  metabolic  syn-
drome  was  defined  according  to  the  National  Cho-
lesterol Education Program Adult Treatment Panel III 
(NCEP-ATP III, 2005), in which central obesity is an 
essential parameter (BMI ≥25) [14]. A modified waist 
circumference cutoff of >90 cm was used in men and 
>80 cm in women [15]. 
 The  metabolic  syndrome  was  then  defined  as 
any individual who had two or more of the four fol-
lowing: 1) high blood pressure (>130/85 mmHg) or 
anti-hypertensive  medication,  2)  elevated  fasting 
blood glucose (>5.6 mmol/L) or anti-diabetic medica-
tion, 3) hypertriglyceridemia (>1.7 mmol/L), and 4) 
low  HDL-cholesterol  (men,  <1.04  mmol/L;  women, 
<1.3 mmol/ L). 
Individuals  meeting  the  following  conditions 
were  defined  as  having  NAFLD:  1)  consuming  less 
than 40 g of alcohol per week, 2) having negative test 
for HBsAg or hepatitis C, and 3) having fat in the liver 
by ultrasound imaging.  
Excessive alcohol intake was defined as alcohol 
intake  >40  g  per  day  for  one  or  more  consecutive 
years. The cause of the abnormal liver tests was de-
fined as unexplained when there was no evidence of 
fatty liver by  ultrasonography, no excessive alcohol 
intake, no HBsAg or anti-HCV, and no other known 
causes of liver damage.  
Statistical analysis 
Statistical  analyses  were  performed  using  SAS 
software (version 8.0). Clinical and biochemical char-
acteristics were compared between men and women 
using Chi-Square test or Fisher’s exact test. Logistic 
regression analysis was used to evaluate relationships 
between abnormal LTs (case group) and normal LTs 
(control group) in the entire survey population. Lo-
gistic  regression  analysis  was  also  used  to  evaluate 
relationships between abnormal LTs (case group) and 
diseased with normal LTs (disease control group) in Int. J. Med. Sci. 2011, 8 
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NAFLD, unexplained cases, HBV, HCV, or metabolic 
syndrome  subgroups.  The  independent  variables 
were age, gender, sleep quality, smoking, BMI, fasting 
plasma glucose, total cholesterol, triglyceride, HDL, 
and LDL. P<0.05 was considered statistically signifi-
cant. 
Results 
Prevalence and etiology of abnormal liver tests  
A  total  of  3791  serum  samples  were  collected 
from 1800 males, and 1991 females in the age group 
18-79  years.  Their  median  age  was  43  years;  32.3% 
were between 18 and 39, 60.5% between 40 and 64, 
and only 7.02% were over 65; 1773 came from urban, 
and 2018 from rural areas.  
The median ALT, AST, GGT, and platelet counts 
in patients without abnormal LTs were 16 U/L, 19.5 
U/L, 16.8 U/L, and 241*109/L, respectively; they were 
41.4 U/L, 30.1 U/L, 69.9 U/L, and 203 X 109/L, re-
spectively, in the abnormal LTs group. Table 1 sum-
marizes  the  prevalence  of  abnormal  liver  tests  ac-
cording to etiology and age. The overall prevalence of 
abnormal liver tests was 14.77%. The noticeable cause 
of abnormal liver tests was excess alcohol consump-
tion alone (18.21%), NAFLD alone (11.61%), metabolic 
syndrome  alone  (25%),  both  NAFLD  and  metabolic 
syndrome (22.14%). 
The  prevalence  first  increased  and  then  de-
creased  progressively  with  increased  age.  Age  was 
also the main factor contributing to NAFLD alone and 
metabolic syndrome alone as well as HBV infection 
and  alcohol  intake.  Nevertheless,  the  prevalence  of 
abnormal  liver  tests  caused  by  HCV  infection  in-
creased progressively with age. Abnormal liver tests 
caused  by  both  NAFLD  and  metabolic  syndrome 
were predominantly observed in the age group 40-64 
years old. The study showed that both NAFLD and 
metabolic  syndrome  were  potentially  important  eti-
ologies  of  presumed  liver  injury  (3.27%).  Etiologies 
such as alcohol intake alone and metabolic syndrome 
alone were more frequent, and NAFLD alone was less 
frequent  in  men.  The  abnormal  liver  tests  occurred 
more frequently in men than in women (416 out of 
1739  subjects,  23.92%  vs.  144  out  of  2052  subjects, 
7.02%; P<0.01) (Table 2). 
Factors associated with abnormal liver tests 
Table 3 shows the results of individual risk fac-
tors and their association with abnormal liver tests. 
The  overall  prevalence  of  abnormal  liver  tests  was 
14.77% (560 out of 3791 subjects). The factors associ-
ated  with  abnormal  liver  tests  were  male  gender, 
mid-old age, poor quality of sleep, smoking, alcohol 
intake, higher fasting plasma glucose, BMI, high total 
cholesterol, hypertriglyceridemia, and elevated LDL. 
However,  except  higher  total  cholesterol,  other  risk 
factors were significantly associated with the devel-
opment of abnormal liver tests in a multiple logistic 
regression analysis.  
 
 
Table 1. Prevalence of Abnormal Liver Tests Classified by Etiology and Age 
Etiological factor  Age (years)  Total (n=3791) 
18~39 (n=1228) n(%)  40~64 (n=2297) n(%)  ≥65 (n=266) n(%)  n(%) (95%CI) 
Alcohol alone  22(1.79)  78(3.4)  2(0.75)  102(2.69)(2.17-3.20) 
HBV (± alcohol)  9(0.73)  47(2.05)  3(1.13)  59(1.56)(1.16-1.95) 
HCV (± alcohol)  4(0.33)  10(0.44)  3(1.13)  17(0.45)(0.23-0.66) 
HBV and HCV (± alcohol)  0(0)  2(0.09)  0(0)  2(0.05)(0.01-0.12) 
NAFLD alone  20(1.63)  40(1.74)  5(1.88)  65(1.71)(1.3-2.12) 
MS alone  41(3.34)  91(3.96)  8(3.01)  140(3.69)(3.09-4.29) 
NAFLD and MS  30(2.44)  86(3.74)  8(3.01)  124(3.27)(2.7-3.8) 
Unexplained  16(1.3)  34(1.48)  1(0.38)  51(1.35)(0.97-1.71) 
Total n(%) (95%CI)  142(11.56)(9.77-13.35)  388(16.89)(15.35-18.42)  30(11.28)(7.47-15.1)  560(14.77)(13.6-15.9) 
Abnormal liver tests: ALT ≥45 IU/L and/or GG T ≥50 IU/L and/or AST ≥45 IU/L and/or platelet counts ≤130 X 109/L; CI, confidence 
interval; NAFLD, non-alcoholic fatty liver; alcohol alone, alcohol intake ≥28 g/d for more than two years; there were no smoking alone or 
poor sleep quality alone groups. 
NAFLD was defined by fatty appearing liver on ultrasound with HBsAg (–), anti-HCV Ab (–), no excessive alcohol consumption, and no 
other known etiologies of liver disease. 
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Table 2. Causes for Abnormal Liver Tests Classified by Gender 
Etiological factor  Male (n=416) n (%)  Female (n=144) n(%)  Total (n=560) n(%)  P value 
Alcohol alone  102(24.51)  0(0)  102(18.21)  <0.05 
HBV (± alcohol)  44(10.57)  15(10.41)  59(10.54)  >0.05 
HCV (± alcohol)  9(2.16)  8(5.55)  17(3.04)  <0.05 
HBV and HCV (± alcohol)  1(0.24)  1(0.69)  2(0.36)  >0.05 
NAFLD  alone  38(9.13)  27(18.75)  65(11.61)  <0.05 
MS  alone  122(29.32)  18(12.5)  140(25)  <0.05 
NAFLD and MS  70(16.82)  54(37.5)  124(22.14)  <0.05 
Unexplained  30(7.21)  21(14.58)  51(9.11)  <0.05 
Total n (%)  416(100)  144(100)  560(100)   
HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine aminotransferase; Abnormal liver tests: ALT ≥45 IU/L and/or GG T ≥50 IU/L 
and/or AST ≥45 IU/L and/or platelet counts ≤130 X 109/L; CI, confidence interval; NAFLD, non-alcoholic fatty liver; alcohol alone, alcohol 
intake ≥28 g/d for more than two years; there were no smoking alone or poor sleep quality alone groups. 
NAFLD was defined by fatty appearing liver on ultrasound with HBsAg (–), anti-HCV Ab (–), no excessive alcohol consumption, and no 
other known etiologies of liver disease. 
 
Table 3. Association of Risk Factors with Individuals With or Without Abnormal Liver Tests by Multiple Analyses 
Risk factor    Abnormal  Liver 
Tests n (%) 
Non-Abnormal  Liver 
Tests n (%) 
Univariate  
OR (95%CI) 
Multiple 
OR (95%CI) 
Age (years)  18~39  142(11.56)  1086(88.44)  1 (reference)   
  40~64  388(16.89)  1909(83.11)  1.55*(1.26-1.91)  1.26*(1.11-1.61) 
  ≥65  30(11.28)  236(88.72)  0.97(0.64-1.47)  0.77(0.48-1.22) 
Gender  Male  416(23.92)  1323(76.08)  1   
  Female   144(7.02)  1908(92.98)  0.24*(0.19-0.29)  0.30*(0.24-0.38) 
Daily alcohol in-
take(g/week) 
<100  377(11.39)  2933(88.61)  1   
  ≥100  183(38.05)  298(61.95)  4.77*(3.86-5.91)  2.57*(1.98-3.32) 
Sleep quality  Good  304(10.7)  2545(89.3)  1   
  Bad   256(27.2)  686(72.80  3.1*(2.5-3.7)  3.1*(2.5-3.8) 
Smoking  NO  265(11.3)  2070(88.7)  1   
  YES  295(20.3)  1161(79.70  1.98*(1.65-2.37)  1.3*(1.1-1.6) 
FPG (mmol/L)  <5.6  399(12.75)  2731(87.25)  1   
  5.6~7.0  107(22.25)  374(77.75)  1.95*(1.54-2.48)  1.10(0.83-1.45) 
  ≥7.0  54(30)  126(70)  2.93*(2.09-4.10)  1.71*(1.15-2.54) 
BMI (kg/m2)  <25  214(8.89)  2193(91.11)  1   
  ≥25  346(25)  1038(75)  3.41*(2.83-4.11)  2.46*(1.98-3.05) 
Triglycerides  <1.7  214(8.02)  2455(91.98)  1   
  ≥1.7  346(30.84)  776(69.16)  5.11*(4.23-6.17)  3.64*(2.93-4.53) 
HDL (mmol/L)  ≥1.3  335(14.47)  1980(85.53)  1   
  <1.3  225(15.24)  1251(84.76)  1.06(0.88-1.27)  1.71(0.56-1.88) 
CHOL (mmol/L)  <6.0  488(13.46)  3131(86.52)  1   
  ≥6.0  72(41.86)  100(58.14)  4.62*(3.36-6.34)  1.40(0.82-2.40) 
LDL (mmol/L)  <4.3  481(13.36)  3118(86.64)  1   
  ≥4.3  79(41.15)  113(58.85)  4.53*(3.34-6.13)  2.16*(1.30-3.61) 
BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose; HDL, high density lipoprotein; LDL, low density lipoprotein; 
CHOL, total cholesterol;  
*P <0.001 vs. reference.  
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Factors associated with abnormal LTs in indi-
viduals with NAFLD, metabolic syndrome, HBV, 
HCV or unexplained subgroups  
We  found  that  male  gender,  poor  quality  of 
sleep, smoking and younger age with increased tri-
glyceridemia,  FPG  and  BMI  were  associated  with 
abnormal LTs in individuals with NAFLD in multi-
variate  analyses.  Meanwhile,  male  gender,  alcohol 
intake,  higher  triglyceridemia,  FPG  and  LDL  were 
associated  with  abnormal  LTs  in  individuals  with 
metabolic syndrome. The prevalence of HBV and an-
ti-HCV  antibody  was  5%  (190/3791)  and  1.1% 
(45/3791). Abnormal LTs were associated with male 
gender,  older  age,  and  high  triglycerides  in 
HBV-positive individuals, but not in anti-HCV anti-
body-positive  individuals.  Abnormal  LTs  in  HBV- 
and  HCV-positive  individuals  was  less  associated 
with  biochemical  or  metabolic  factors.  Male  gender 
and high triglyceridemia were associated with indi-
viduals with abnormal LTs of unexplained cause (Ta-
ble 4). 
 
 
Table 4. Multiple Logistic Regression Analysis of Risk Factors Associated with Abnormal Liver Tests in Different Diseases  
    HBV group  HCV group  MS group  NAFLD group  Unexplained 
group 
% (case/total )*    32.1(61/190)  42(19/45)  32.85(264/814)  31.7(189/596)  2.37(51/2155) 
Risk factor    Abnormal Liver Tests odds ratio (95%confidence interval) 
 
Age (years)  18~39  1(reference)      1   
  40~64  6.33*(4.69-8.90)      0.63(0.39-1.02)   
  ≥65  11.61*(8.41-15.41)      0.40*(0.18-0.91)   
Gender  Male  1    1  1  1 
  Female   0.37*(0.17-0.82)    0.22*(0.15-0.33)  0.24*(0.16-0.36)  0.46*(0.26-0.67) 
Daily alcohol in-
take(g/week) 
<100      1     
  ≥100      1.77*(1.42-2.80)     
Sleep quality  Good        1   
  Bad        26*(12-59)   
Smoking   No         1   
  Yes        2.5*(1.2-5)   
FPG (mmol/L)  <5.6      1  1   
  5.6~7.0      0.90(0.61-1.33)  1.13(0.68-1.88)   
  ≥7.0      1.45*(1.25-2.48)  1.40*(1.14-2.65)   
BMI (kg/m
2)  <25        1   
  ≥25        1.69*(1.42-2.79)   
Triglyceride 
(mmol/L) 
<1.7  1    1  1  1 
  ≥1.7  2.77*(1.89-3.07)    1.95*(1.32-2.88)  2.26*(1.52-3.35)  5.12*(3.47-7.60) 
LDL (mmol/L)  <4.3      1     
  ≥4.3      2.96*(1.8-3.81)     
HBV, hepatitis B virus; HCV, hepatitis C virus; MS, metabolic syndrome; BMI, body mass index; FPG, fasting plasma glucose; HDL, high 
density lipoprotein; LDL, low density lipoprotein; CHOL, total cholesterol; NAFLD, non-alcoholic fatty liver; alcohol alone; *P <0.001 vs. the 
reference.  
% (case/total), *percent of abnormal liver tests in various disease subgroups. 
 
 
Discussion 
Based on earnings in the middle of the income 
range of most of the inhabitants, and the sex and age 
distribution, at the level of life, economic and cultural 
development  in  the  province,  Dehui  City  is  repre-
sentative  of  JiLin  in  general.  A  multistage, 
tiered-system sampling method used to control selec-
tion bias provided a study sample that was a good 
representative of the target population in JiLin. 
The population in our study had dietary habits 
that are different from those of populations in south-
ern China and other industrialized areas. In the pre-
sent study, we found a very high prevalence of ab-
normal  liver  tests  in  the  adult  population  (14.77%) 
and elevated serum aminotransferase levels (11.1%). Int. J. Med. Sci. 2011, 8 
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In  previous  community-based  studies  in  Italy,  the 
percentage of individuals with persistently abnormal 
LTs  was  12.7%  [1].  Data  from  the  Third  National 
Health and Nutrition Examination Survey, which was 
conducted in the United States from 1988 to 1994, in-
dicated that 7.9% of adults had elevated serum ami-
notransferase levels [10]. The prevalence of elevated 
ALT was reported to be 11% in Taiwan [12]. There-
fore, the observed prevalence of 14.7% of abnormal 
liver tests or elevated serum aminotransferase levels 
in the current study in Jilin, China was relatively high. 
This  percentage  would  have  been  lower  if  the 
upper  limits  of  normal  for  aminotransferases  were 
higher. However, the public health and clinical utility 
of altering them is debatable [16]. The causes of ab-
normal liver tests may vary in different geographic 
areas. The factors associated with abnormal liver tests 
were male gender, old age, alcohol intake, poor qual-
ity of sleep, smoking and metabolic factors (e.g., hy-
pertriglyceridemia), which confirms data in previous 
studies [1, 12]. Metabolic factors accounted for most of 
the cases of abnormal liver tests in present study.  
ALT  is  more  specific  for  active  hepatocellular 
damage. The prevalence of elevated AST reflects the 
incidence  of  other  conditions  besides  liver  damage. 
Therefore, it is not surprising that the combination of 
AST  and  thrombocytopenia  would  be  higher  than 
ALT  and  thrombocytopenia.  An  epidemiological 
survey published in 2000 revealed that 10.74% of the 
Chinese population had positive hepatitis B surface 
(HBsAg), indicating that China is one of the highest 
endemic  regions  of  HBsAg  in  the  world  [17].  The 
prevalence of HCV was low in China, with one report 
showing  only  a  3%  prevalence  rate  in  the  Shaanxi 
Province, China [18]. Hepatitis viral infection is not 
the  most  common  cause  of  chronic  liver  disease  in 
Jilin, China. We found that the prevalence of HBsAg 
carriers was 5%, and that it decreased with older age, 
which would currently make the region to be consid-
ered as an intermediate endemic region.19-21 
In  addition,  our  data  on  HBsAg  positivity 
(190/3791=5%) were more than two-fold lower than 
that of 10.7% in the pre-vaccination era (Table 4). Ten 
years ago, the seroprevalence of positive-HBsAg was 
7%, 8%, and 9% in the Shaanxi, Shangdong, and Jilin 
Provinces, respectively [18, 22-23]. In the 65 and older 
age group, abnormal liver tests attributable to HBV 
were relatively low. Explanations for this include the 
known increase in spontaneous seroconversion with 
duration of infection, and a known tendency of HBV 
viral load to decline with duration of infection. In ad-
dition, progressive mortality due to HBV-related se-
quelae may have led to a decreased prevalence of in-
dividuals with HBV-infection in the 65 and older age 
group  [24].  In  contrast,  the  prevalence  of  anti-HCV 
antibody  was  1.1%,  and  the  risk  significantly  in-
creased  with  older  age.  The  current  data  are  con-
sistent  with  those  of  other  studies  [25].  Adult  im-
munization for HBV is an effective means to decrease 
the  seroprevalence  of  HBsAg,  but  there  is  no  clear 
explanation for the observations on HCV seropreva-
lence. 
The prevalence rates of metabolic syndrome and 
NAFLD  in  the  abnormal  LTs  group  were  different 
between the genders. It is not clear whether gender is 
an independent risk factor for them [26]. Insulin re-
sistance is considered to be a common denominator of 
NAFLD because insulin resistance is very common in 
obesity,  and  hypertriglyceridemia,  and  is  the  hall-
mark of type 2 diabetes mellitus [27]. The pathogene-
sis of NAFLD is hypothesized to be the ‘two-hit the-
ory’ and is related to metabolic syndrome [1, 4]. The 
first  hit  consists  of  steatosis  induced  by  insulin  re-
sistance, and the second hit consists of oxidative stress 
in  mitochondria  of  lipid-laden  hepatocytes.  When 
fatty liver is associated with necroinflammation and 
fibrosis  [28],  NAFLD  can  progress  to  cirrhosis  and 
hepatocellular  carcinoma  [29].  The  results  from  our 
current study may reflect the Westernization of die-
tary habits and sedentary lifestyles in this population. 
These  data  are  also  consistent  with  literature  sug-
gesting that metabolic syndrome is a predictor of fi-
brosis  and  has  an  independent  pathogenic  role  in 
NAFLD  [30].  The  apparently  higher  prevalence  of 
NAFLD in this population compared to previous re-
ports probably reflects the fact that the population is 
rapidly changing towards increasing obesity. 
Male gender and metabolic factors (e.g., triglyc-
eridemia, body mass index, and low density lipopro-
tein)  were  risk  factors  for  abnormal  LTs  of  unex-
plained cause in previous surveys from a Mediterra-
nean town and Taiwan [1, 12]. Medications such as 
anti-hypertensives,  lipid-lowering,  or  anti-diabetic 
drugs  were  other  possible  causes  of  abnormal  liver 
tests. When these were excluded in the present study, 
the risk factors  were also  associated with abnormal 
LTs in individuals with unexplained causes. A reason 
for the cases of unexplained causes may have been the 
inclusion of cases of early stage diseases which were 
not diagnosed due to a lack of signs and symptoms 
(e.g., metabolic syndrome).  
Our present study showed that metabolic factors 
(e.g., triglyceridemia, body mass index, and low den-
sity lipoprotein) were less associated with abnormal 
LTs in individuals with HBV or HCV infection with 
the exception of gender in the regression models. The 
reason for this may be that the number of people with 
HBV and HCV was low. In a multiple logistic regres-Int. J. Med. Sci. 2011, 8 
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sion model, generally there should be ten events for 
each variable. The abnormal LTs in individuals with 
HBV or HCV may have been due to the viral infec-
tions [31]. Poor quality of sleep, and smoking were 
associated  with  abnormal  liver  tests  in  individuals 
with NAFLD and the other groups, suggesting that 
those factors may promote abnormal LTs in individ-
uals with NAFLD and the other groups. Cessation of 
smoking and decreasing alcohol intake may amelio-
rate liver damage. 
One of the limitations in the present study is that 
the diagnosis of fatty liver was based on ultrasound 
imaging, which was  not confirmed by liver biopsy, 
the gold standard for the assessment of liver histology 
and a key test to diagnose NAFLD.  
Conclusion 
The prevalence of HBV and HCV was found to 
be  lower  than  previously  reported.  Therefore,  ab-
normal  LTs  contributed  by  viral  infections  are  not 
likely to be as significant in this geographic area as in 
the past. In individuals with abnormal LTs, metabolic 
syndrome  alone,  NAFLD  alone,  and  alcohol  intake 
were found to be important etiological factors, espe-
cially both MS and NAFLD. The estimated prevalence 
and etiologies of abnormal LTs may be useful in im-
plementing strategies for reducing the potential bur-
den of CLD. 
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